M
Michael Bamberg
Researcher at University of Tübingen
Publications - 411
Citations - 14528
Michael Bamberg is an academic researcher from University of Tübingen. The author has contributed to research in topics: Radiation therapy & Survival rate. The author has an hindex of 60, co-authored 409 publications receiving 13780 citations.
Papers
More filters
Journal ArticleDOI
NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide
Wolfgang Wick,Christian Hartmann,Corinna Engel,Mandy Stoffels,Jörg Felsberg,Florian Stockhammer,Michael Sabel,Susanne Koeppen,Ralf Ketter,Richard Meyermann,Marion Rapp,C Meisner,Rolf D. Kortmann,Torsten Pietsch,Otmar D. Wiestler,Ulrike Ernemann,Michael Bamberg,Guido Reifenberger,Andreas von Deimling,Michael Weller +19 more
TL;DR: IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation and associated with prolonged PFS in the chemotherapy and radiotherapy arm.
Journal ArticleDOI
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
Susanne Krege,Jörg Beyer,Rainer Souchon,Peter Albers,Walter Albrecht,Ferran Algaba,Michael Bamberg,István Bodrogi,Carsten Bokemeyer,Eva Cavallin-Ståhl,Johannes Classen,C Clemm,Gabriella Cohn-Cedermark,Stéphane Culine,Gedske Daugaard,Pieter H.M. De Mulder,Maria De Santis,Maike de Wit,Ronald de Wit,H. G. Derigs,Klaus Peter Dieckmann,Annette Dieing,Jean Pierre Droz,Martin Fenner,Karim Fizazi,Aude Flechon,Sophie D. Fosså,Xavier Garcia del Muro,Thomas Gauler,Lajos Géczi,Arthur Gerl,Jose Ramon Germa-Lluch,Silke Gillessen,Jörg T. Hartmann,Michael Hartmann,Axel Heidenreich,Wolfgang Hoeltl,Alan Horwich,Robert Huddart,Michael Jewett,Johnathan Joffe,William G. Jones,László Kisbenedek,Olbjørn Klepp,S. Kliesch,Kai Uwe Koehrmann,Christian K. Kollmannsberger,Markus A. Kuczyk,Pilar Laguna,Oscar Leiva Galvis,Volker Loy,Malcolm David Mason,Graham M. Mead,Rolf Mueller,Craig R. Nichols,Nicola Nicolai,Tim Oliver,D. Ondruš,Gosse O N Oosterhof,Luis Paz Ares,Giorgio Pizzocaro,Jörg Pont,Tobias Pottek,Thomas Powles,Oliver Rick,Giovanni Rosti,Roberto Salvioni,Jutta Scheiderbauer,Hans U. Schmelz,Heinz Schmidberger,Hans-Joachim Schmoll,Mark Schrader,Felix Sedlmayer,Niels E. Skakkebæk,Aslam Sohaib,Sergei Tjulandin,Padraig Warde,Stefan Weinknecht,Lothar Weissbach,Christian Wittekind,Eva Winter,Lori Wood,Hans von der Maase +82 more
TL;DR: F refinements in the treatment of early- and advanced-stage testicular cancer have emerged from clinical trials, and expert clinical skills will continue to be one of the major determinants for the prognosis of patients with germ cell cancer.
Journal ArticleDOI
High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
Eckhard Thiel,Agnieszka Korfel,Peter Martus,Lothar Kanz,Frank Griesinger,Michael Rauch,Alexander Röth,Bernd Hertenstein,Theda von Toll,Thomas Hundsberger,H. Mergenthaler,Malte Leithäuser,Tobias Birnbaum,Lars Fischer,Kristoph Jahnke,Ulrich Herrlinger,Ludwig Plasswilm,Thomas Nägele,Torsten Pietsch,Michael Bamberg,Michael Weller,Michael Weller +21 more
TL;DR: The hypothesis was that the omission of whole brain radiotherapy does not compromise overall survival, with a non-inferiority margin of 0·9, and the primary hypothesis was not proven.
Journal ArticleDOI
Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.
Rolf D. Kortmann,Joachim Kühl,Beate Timmermann,Uwe Mittler,Christian Urban,Volker Budach,Eckart Richter,Normann Willich,Michael Flentje,Frank Berthold,Slavc I,Johannes Wolff,Christoph Meisner,Otmar D. Wiestler,Nils Sörensen,Monika Warmuth-Metz,Michael Bamberg +16 more
TL;DR: Maintenance chemotherapy would seem to be more effective in low-risk medulloblastoma, especially in patients older than 6 years of age, and quality control of radiotherapy revealed correct treatment in more than 88% for dose prescription, more than 90% for coverage of target volume, and 98% for field matching.
Journal ArticleDOI
Cellular basis of radiation-induced fibrosis
TL;DR: The cellular mechanism of radiation-induced fibrosis can be seen as a multicellular process involving various interacting cell systems in the target organ resulting in the fibrotic phenotype of the fibroblast/fibrocyte cell system.